Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect

Atherosclerosis. 2016 Nov:254:300-302. doi: 10.1016/j.atherosclerosis.2016.09.013. Epub 2016 Oct 13.

Authors

Luiz Sérgio F de Carvalho¹, Hiroshi Yoshida²

Affiliations

¹ Cardiology Department, State University of Campinas (Unicamp), Campinas, SP, Brazil. Electronic address: luizsergiofc@gmail.com.
² Department of Laboratory Medicine, Jikei University Kashiwa Hospital, Chiba, Japan. Electronic address: hyoshida@jikei.ac.jp.

PMID: 27745881
DOI: 10.1016/j.atherosclerosis.2016.09.013

No abstract available

Keywords: Clinical trials; Hypercholesterolemia; Lipid modifying drugs; PCSK9 inhibitors.

Publication types

Editorial
Comment

MeSH terms

Anticholesteremic Agents
Drug Therapy, Combination
Dyslipidemias
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypercholesterolemia*
Proprotein Convertase 9*

Substances

Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 protein, human
Proprotein Convertase 9